0001193125-26-116154
SEC filingEledon Pharmaceuticals issued its fourth quarter and full year 2025 financial results, reporting a net loss of $45.6 million or $0.52 per share, R&D expenses of $66.3 million, and cash of $22.8 million as of December 31, 2025. The company highlighted clinical progress for tegoprubart, including orphan drug designation for liver transplantation and positive 24-month kidney transplant data.